Department of Pharmaceutical Sciences, North South University, Plot 15, Block B, Bashundhara, Dhaka, 1229, Bangladesh.
Stem Cell Res Ther. 2017 Oct 10;8(1):222. doi: 10.1186/s13287-017-0679-y.
The human umbilical cord has been studied extensively in the past two decades. It is free of ethical dilemmas, non-tumorigenic, and less immunogenic and thus provides a significant advantage over other stem cell sources. The cord lining yields both mesenchymal and epithelial stem cells. The mesenchymal cells have been appraised at length by many researchers, which led to the current review focusing on the cord lining epithelial cells (CLECs). These cells have high proliferative capacity and their superior harvest and multiplication, using the revolutionary CellOptima technology, makes them better candidates in comparison to contemporary adult stem cells. Following 30 replication cycles these cells have been observed to retain their stemness, with their phenotype and karyotype intact. However, their remarkable immunosuppressant properties, protecting self as well as co-transplanted allografts from rejection, are what truly define their transplantation potential. They have been successfully applied to many chronic conditions, using animal models, including type 1 diabetes, limbal stem cell deficiency, burn injuries, and wound healing, etc. with encouraging results.
This review first discusses some of the advantages afforded by CLECs over other stem cell lines and then delineates their potential use in various clinical applications. Clinical trials using CLECs are currently underway in the US in collaboration with CellResearch Corp. and their potential positive findings will help garner an FDA approval, likely leading to the eventual commercialization of this promising technology.
在过去的二十年中，人们对人类脐带进行了广泛的研究。它没有伦理道德上的问题，无致瘤性，免疫原性较低，因此与其他干细胞来源相比具有显著优势。脐带衬里产生间充质和上皮干细胞。许多研究人员对间充质细胞进行了详细评估，这导致目前的综述侧重于脐带衬里上皮细胞（CLECs）。这些细胞具有较高的增殖能力，通过革命性的 CellOptima 技术进行高效收获和增殖，使它们比当代成人干细胞更具优势。在经历 30 次复制周期后，这些细胞仍保留其干细胞特性，其表型和核型保持完整。然而，它们显著的免疫抑制特性，既能保护自身，又能保护共移植的同种异体移植物免受排斥，这真正定义了它们的移植潜力。它们已成功应用于许多慢性疾病的动物模型中，包括 1 型糖尿病、角膜缘干细胞缺乏症、烧伤和伤口愈合等，取得了令人鼓舞的结果。
本综述首先讨论了 CLECs 相对于其他干细胞系的一些优势，然后阐述了它们在各种临床应用中的潜在用途。目前在美国，CellResearchCorp 正在进行使用 CLECs 的临床试验，其潜在的积极发现将有助于获得 FDA 批准，可能最终使这项有前途的技术商业化。
